Retatrutide (20mg)

Higher-Capacity Vial for Extended Research Protocols

Retatrutide (20mg) is supplied in Australia by Aussie Peptides with fast domestic shipping to all states and territories.

The 20mg vial provides twice the compound of the 10mg vial — same purity, same batch-verified CoA, better value per milligram, and fewer reconstitution cycles across an extended research protocol.

Retatrutide’s triple-receptor activity distinguishes it from other compounds in weight-loss research. Phase 2 clinical trials reported a mean body weight reduction of up to 24% over 48 weeks — outperforming semaglutide and tirzepatide in head-to-head data. The mechanism targets three pathways simultaneously: appetite regulation via GLP-1, fat metabolism and insulin sensitivity via GIP, and increased energy expenditure via glucagon receptor activation.

Key Research Areas

• Fat Loss Research — including visceral adiposity
• Appetite Regulation — reduced food intake and caloric studies
• Metabolic Markers — blood pressure, lipids, waist circumference
• Energy Expenditure — via glucagon receptor activation
• Comparative Research — outperforms semaglutide and tirzepatide in head-to-head data

Supplied as lyophilized powder at ≥99% purity, verified by HPLC and mass spectrometry. 20mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.